Dr. Samuels has 22 years of diverse pharmaceutical experience in large pharma and biotech settings. He has worked in corporate venture, business development, M&A, clinical development, strategy and investor relations.
Dr. Tsukerman received his Ph.D. from the Hebrew University at the lab of Prof. Mandelboim and has authored over 20 publications and numerous patents and is an expert in the field of cellular and molecular immunology.
Dr. Cinamon has a vast experience in leading early stage drug development. After a post-doctorate fellowship at the University of California, San Francisco, Dr. Cinamon joined Teva Pharmaceutical Industries.
Dr. Samuels has 22 years of diverse pharmaceutical experience in large pharma and biotech settings. He has worked in corporate venture, business development, M&A, clinical development, strategy and investor relations.
Ms. Sokolov is a medical technology executive with extensive experience in innovation, investments, business development and strategy. She is a pharmacist with a B.Pharm. degree from Heb. U and an MBA from Kellogg.
Before leading Integra, Dr. Patt held the position of VP Biz Dev, Global Branded Products at Teva Pharmaceutical Industries, where she led teams of search & evaluation and early stage drug development and business transactions.
Mr. Buchman has over 20 years of experience in senior corporate financing, mergers & acquisitions, investor relations, operational and business development. In addition, he has extensive experience in equity and debt financing
Dr. Khleif has published several studies on the mechanisms of tumor-induced suppression in animal models and has overcome such inhibitions by developing strategies that have been translated into clinical trials.
As a physician-scientist, Dr. Cohen also leads a laboratory that studies novel cancer treatments, including immunotherapy, and has made major contributions in understanding how targeted cancer therapies work.
Prof. Mandelboim received his Ph.D. in Immunology from the Weizmann Institute of Science, followed by a post-doctorate fellowship at the Harvard Medical School. To date, he has published more than 180 scientific papers.
Prof. Jonjic is a world leader in the field of viral immunology. Over the years he was awarded with many grants and prizes for his achievements and held many executive positions within the University of Rijeka and in national Croatian Societies.